A double blind controlled randomised trial of patients undergoing unilateral primary cemented total knee replacement. The objective is to find out whether Tranexamic acid will reduce blood loss significantly after total knee replacement when applied topically.
Inclusion Criteria
- Undergoing unilateral primary cemented total knee replacement
Patient Exclusions
- Undergoing unilateral primary total knee replacement for trauma or tumour
- Allergic to Tranexamic acid
- Bleeding tendency (e.g. Haemophilic and platelets disorders)
- Warfarin, treatment dose of LMWH or conventional heparin
- History of DVT and pulmonary embolism
- Female subjects of child bearing potential must have a negative pregnancy test
Concomitant treatment
Permitted therapies include:
- Aspirin
- Subcutaneous prophylactic conventional or LMW heparin
|
If you require any help, please contact: Sattar Alshryda |
|
Randomisation service provided by: Sealed Envelope™.com